Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer

Developing new targeted therapy for pancreatic cancer is one of the major current challenges in cancer research. KRAS mutations and miRNA dysregulation (e.g. miR-21-5p oncomiR) play key roles in Pancreatic Ductal Adenocarcinoma (PDAC), leading to rapid progression of the disease. As the KRAS mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilles, Maud-Emmanuelle, Hao, Liangliang, Brown, Kaelyn, Lim, Jihoon, Bhatia, Sangeeta N., Slack, Frank J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731108/
https://www.ncbi.nlm.nih.gov/pubmed/31523393
http://dx.doi.org/10.18632/oncotarget.27160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731108/
https://www.ncbi.nlm.nih.gov/pubmed/31523393
http://dx.doi.org/10.18632/oncotarget.27160

Ejemplares similares